KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Common Equity (2016 - 2026)

Emergent BioSolutions has reported Common Equity over the past 17 years, most recently at $523.1 million for Q1 2026.

  • For Q1 2026, Common Equity fell 5.36% year-over-year to $523.1 million; the TTM value through Mar 2026 reached $523.1 million, down 5.36%, while the annual FY2025 figure was $522.6 million, 8.24% up from the prior year.
  • Common Equity for Q1 2026 was $523.1 million at Emergent BioSolutions, roughly flat from $522.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $1.6 billion in Q1 2022 and troughed at $386.3 million in Q2 2024.
  • A 5-year average of $833.1 million and a median of $649.3 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: plummeted 59.66% in 2024 and later surged 38.8% in 2025.
  • Year by year, Common Equity stood at $1.4 billion in 2022, then crashed by 53.21% to $649.3 million in 2023, then decreased by 25.64% to $482.8 million in 2024, then increased by 8.24% to $522.6 million in 2025, then rose by 0.1% to $523.1 million in 2026.
  • Business Quant data shows Common Equity for EBS at $523.1 million in Q1 2026, $522.6 million in Q4 2025, and $582.5 million in Q3 2025.